Clinical Trial Update: Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for RYZ101 (225Ac-DOTATATE) evaluating somatostatin receptor–expressing ER-positive, HER2-negative metastatic or unresectable br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• RYZ101

Snippet

Sponsor: RayzeBio, Inc. | Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING